 | |
 | |
| Clinical data | |
|---|---|
| Other names | (S)-3-[4-(butylthio)-1,2,5-thiadiazol-3-yl]quinuclidine |
| Routes of administration | oral |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C13H21N3S2 |
| Molar mass | 283.45 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Vedaclidine (INN,[1]: 180 codenamedLY-297,802,NNC 11-1053) is an experimentalanalgesicdrug which acts as a mixedagonist–antagonist atmuscarinic acetylcholine receptors, being a potent and selectiveagonist for theM1 andM4 subtypes, yet anantagonist at theM2,M3 andM5 subtypes.[2][3] It is orally active and an effective analgesic over 3× the potency ofmorphine, with side effects such assalivation andtremor only occurring at many times the effective analgesic dose.[4][5][6] Human trials showed little potential for development of dependence or abuse,[7] and research is continuing into possible clinical application in the treatment ofneuropathic pain andcancer pain relief.[8]
